Invion Limited (ASX:IVX) Interview - Next-generation Photodynamic Therapy(PDT) to treat cancer.

BPC is excited to present an exclusive conversation with Thian Chew, Executive Chair and CEO of Invion Limited (ASX:IVX), discussing their groundbreaking developments in Next-Generation Photodynamic Therapy (PDT) to treat cancer and a range of other diseases.

Discover the advancements of Invion's innovative approach that enhances existing PDT methods to combat cancer through a targeted and less-invasive treatment approach.


Join host Jack Colreavy, CFA, as he explores the unique aspects of Invion's Next-Gen PDT compared to existing offerings and provides the latest updates on its clinical trials across multiple cancers with Thian.

Uncover the potential of photodynamic therapy and its market implications by following Invion on the ASX under the ticker code IVX.

For further information on this #InvestmentOpportunity, please contact James Whelan.